Previous Close | 10.25 |
Open | 10.32 |
Bid | 10.42 x 100 |
Ask | 10.62 x 100 |
Day's Range | 10.29 - 10.56 |
52 Week Range | 1.81 - 15.05 |
Volume | |
Avg. Volume | 255,980 |
Market Cap | 398.673M |
Beta (5Y Monthly) | 2.02 |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Solid Biosciences' (SLDB) novel gene-therapy candidate, SGT-003, gets FDA's Rare Pediatric Disease Designation for the treatment of Duchenne muscular dystrophy.
Solid Biosciences is shrugging off several messy years in gene therapy development. The biotech stock has gotten a triple-digit boost.
In this article, we will take a detailed look at 14 Stocks With Heavy Insider Buying In 2024. For a quick overview of such stocks, read our article 5 Stocks With Heavy Insider Buying In 2024. Markets await latest inflation numbers and the debate regarding soft vs hard landing is expected to persist in the Wall Street for months […]